Items Tagged ‘crpc’

February 22, 2018

Xtandi® A New Standard Treatment for Men with Non-Metastatic Castration-Resistant Prostate Cancer?


CancerConnect News:  Results from the Phase 3 PROSPER clinical trial in patients with non-metastatic Castration-Resistant Prostate Cancer (CRPC) were released this week at the 2018 Genitourinary Cancers Symposium in San Francisco and demonstrate that the use of Xtandi® (enzalutamide) plus androgen deprivation therapy (ADT) significantly reduced the risk of developing metastases or death by 71 […]

View full entry

Tags: adt, androgen deprivation therapy, castration-resistant prostate cancer, crpc, enzalutamide, News, Prostate Cancer, PSA, rising prostate specific antigen, xtandi